In-Situ Forming Gel (Kydes)

Description: In-situ forming gel comprised of low molecular weight poly (?-caprolactone) (PCL) and biocompatible solvents. The solvent in the polymer solution dissipates post-injection, leaving behind a biodegradable gel depot that slowly releases levonorgestrel.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

Duration: 6 months

  • single injection

Dose: TBD

Active Pharmaceutical Ingredient (API):
  • levonorgestrel

Inactive material: polycaprolactone (PCL)

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: KYDES Pharmaceuticals, FHI 360

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Began discovery in: 2016

Active Development: Yes

Status Details:
  • Feasibility studies of injectable in situ gel systems with low initial burst release followed by constant release profiles, in vitro.

Additional Information


Vertical Tabs